Searchable abstracts of presentations at key conferences in endocrinology

ea0022p600 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Usefulness of cabergoline determination by mass spectrometry during prolactinoma treatment

Badiu Corin , Caragheorgheopol Andra , Jercalau Simona Verzea , Silvestro Luigi

Prolactinoma (PRM) treatment is based upon dopamine agonists, cabergoline (CAB) being one of the most used in the last decade. Sensitivity to CAB varies in terms of tumour volume and PRL secretion, up to 8–15% of PRM being defined as resistant. Since it is known that increasing the dosage improves the response rate, we aimed to measure plasma CAB levels in PRM patients under this treatment in a prospective interventional study.Patients and methods: ...

ea0022p403 | Endocrine tumours &amp; neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Pheochromocytoma: seconds from disaster

Jercalau Simona Verzea , Dobrescu Ruxandra , Stefanescu Ana Maria , Beuran Mircea , Badiu Corin

A 50–year-old female with a 2 year-history of hypertension and diabetes was admitted to a county hospital, where treatment with clonidine and beta-blockers was started, without success. Abdominal CT showed a large left adrenal tumour, and her initial blood pressure (BP) was over 300/170 mmHg, which dropped to 80/30 mmHg. She was transferred for evaluation of a possible pheochromocytoma (PHEO). At admission her BP was 260/160 mmHg, heart rate (HR) 120 bpm, with anxiety, di...